Showing 1-10 of about 160 articles.
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Therapeutics US, Inc
-Amended agreement encompasses enhanced manufacturing collaboration and regulatory support -Accelerates milestone payments to Nabriva, including fourth quarter 2020 payment of $1 million DUBLIN,...
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Nabriva Therapeutics US, Inc
-Relaunch of Xenleta® and Sivextro® commenced in late September- - Type A Meeting with FDA for Contepo™ held on October 30th - -Conference call today at 4:30 p.m. Eastern Time- DUBLIN, Ireland,...
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Nabriva Therapeutics US, Inc
-- Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at risk of...
Nabriva Therapeutics US, Inc
-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship -CONTEPO first Qualified Infectious Disease Product to receive NTAP...
Showing 1-10 of about 160 articles.
